about
Fever of unknown origin, infection of subcutaneous devices, brain abscesses and endocarditis.Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.IntegoTM Infusion System: cost effectiveness analysis focusing on dosimetry, sterility and management.(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy.Endobronchial/Endoesophageal Ultrasound (EBUS/EUS) Guided Fine Needle Aspiration (FNA) and 18F-FDG PET/CT Scanning in Restaging of Locally Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Chemo-radiotherapy: A Mono-institutional Pilot ExperiRole of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.111In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significance.Radiation dosimetry of 18F-fluorocholine PET/CT studies in prostate cancer patients.Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index.FDG PET/CT in autoimmune pancreatitisErratum to: 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II studyProlonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G)
P50
Q31032402-76C71F63-B37D-445D-B27C-47B82EBEE3B1Q38546399-0A381B8B-D33A-41C7-8018-94C9F1C75CE8Q39624676-B67B5E25-C5FB-40CD-A504-5DA669CAA38EQ41161118-2BD487AD-5C00-43A2-B2EF-5F81D5DF6029Q42183357-BCD6BD3B-6123-4380-9E4E-E4CA2D5BC21FQ42460939-D36876A9-59AD-4A78-A549-E60FBE11F333Q43803622-F78FA20C-B327-4BB1-A277-74E7312F54DDQ44453209-100C19B1-7C42-44F1-A973-35483474617BQ44965550-7A0DF0C9-89F8-4EE1-94C7-F94F9DCE6159Q46401061-74CA76C3-091A-45EA-B43D-3C8777A759EDQ49506143-740F9D11-71B9-431F-8FCA-7A60D92D1B21Q56974117-4DE1D49E-3E98-45BE-BBFA-553F4B5C597AQ63342916-A88B6160-5CCA-4EF1-BBFD-84149594503FQ63342918-A9CD4660-3AD3-4B77-B940-4E2C13FC45F7Q85210446-EE00D181-6DC9-4D09-AE59-EB0CA4D5A9C9
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-7455-6253
@en
name
Federica Matteucci
@ast
Federica Matteucci
@en
Federica Matteucci
@es
Federica Matteucci
@nl
type
label
Federica Matteucci
@ast
Federica Matteucci
@en
Federica Matteucci
@es
Federica Matteucci
@nl
prefLabel
Federica Matteucci
@ast
Federica Matteucci
@en
Federica Matteucci
@es
Federica Matteucci
@nl
P106
P1153
14619684200
57190109443
P21
P31
P496
0000-0001-7455-6253